Dual-targeting strategies for cancer and diabetes: Converging pharmacological pathways and repurposed therapies - PubMed
5 days ago
- #drug-repurposing
- #diabetes
- #cancer
- Dual-targeting strategies address both cancer and type 2 diabetes (T2DM) due to their bidirectional association.
- Shared mechanisms include insulin/IGF-1 signaling, chronic inflammation, oxidative stress, and metabolic reprogramming.
- Key pathways involved are PI3K/Akt/mTOR and AMPK, which regulate cell proliferation, survival, and glucose metabolism.
- Repurposed anti-diabetic drugs like metformin, SGLT2 inhibitors, and statins show anticancer potential.
- Biologics (canakinumab, tocilizumab) and natural compounds (curcumin, resveratrol, berberine) offer dual benefits via anti-inflammatory and metabolic pathways.
- Preclinical and clinical data support repurposing anti-diabetic agents for oncology, though biomarker-based patient selection may improve efficacy.
- Emerging strategies include immunometabolism, gut microbiota modulation, and gene-based interventions for integrated care.
- Dual-targeting aims to optimize outcomes, reduce toxicities, and improve survival in patients with overlapping cancer and metabolic disease.
- Future research should focus on precision therapies, multidisciplinary management, and including metabolic parameters in oncology trials.